R E

皿e紐st in hu皿anぐ脆nical s血中based on皿S ce皿s
The first in human c=nical study based on iPS ce=s was conducted
in 2014, beMat｢ix c○看lagen A丁was selected and used for retinaIpigment epithe=al sheet,

Masayo Takahashi, in.D., ph.D.
RiKEN Center For DevelopmentaI Bioiogy●●Gelatin is a material indispensable and pro鵬ing for drug delivery system

More than 1 ,000 patients of intractable diseases weree冊cient看y treated to heal with the geiatin DDS technology

of growth factor release･Yasuhiko Tabata, Ph.D.,D.Med.Sci.,D.Pharm.
institute for Frontierしife and Medical Sciences, Kyoto Unjve｢sity"Low endotoxin levelof beMatrix gelatin was key!

beMatrix gelatin is used in Soium lV, a resorbable bone void fi=e｢, which isan osteoconductive implant sew‑ng as a sca什old for the in‑gr〇両h of newbone, Solum IV forms a cohesive and adhesive consistency upon hyd｢ationa=owmg the shape of the implant to conform to the defect,
Kevin Dunwo巾h, C各O & Founder
Ce冊ng Biosciences

貯‑甲∞ Nitta Gelatin lnc. www.nitta‑gelatin.co.jp/english/#輯一‑

beM土ixADVERTISEMENT FEATU RE[ insideview ]巳X弘NDING TH巳HORIZONS FOR COししAG巳N‑
BAS巳D BIOM巳D工CAしMAT巳R工AしS
A conversation with YoSUK且HIRAoKA, pr ncipal research sdentist at Nitta Gelatin I=c′ Japan

N冊a Geiat両nc provides world‑dass c〇日agen′ gelatin and coilagen peptide products derived frombovine, porcine and fish sources that are widely used両he pharmaceutical, cosmetics, adhesives

and food industries.The company′s po｢tfoiio began with g山es for musica出struments and gelatinsfor photographic f出回as since evolved to meet changing demands over many decades′ today

supplying an innovative line‑up of materiais for biomedical use･and gelatin biomaterials that are

What impact are medìalcustomers. Planning dinicai

found within the ext｢ace冊iar

a葛yanくes having on thetrials was the next step andmatrix (ECM), an important

not only of exceptiona=y highdevelop軸eれt o書biomateria!s?

therefore reducing endotoxin

constituent of many of thequality but a葛so control the level ofDuring the past decade therelevels was critical for this type oftissues in the human body andendotoxins, viruses and bacteria,

have been major advances in

research because this system isin other vertebrates. Geiatin

stem ce= research, regenerative

being introduced into the humanis a heaトdenatured productgelatin products are vaiuabie

medidne and transplantation.

body in c=nical app=cationsof coiiagen, and hydroiysed

for many other heaithca｢egelatin (also known as coilagen

applications due to theirCe= therapy and gene therapy

As we knew that dry heatin addition, our co=agen andproducts are evolving at aste硝sation, autociaving andpeptide) can be made via

absorbent, protective andcorresponding pace. Newf冊｢ation methods couid not be

enzymatic hydroiysis･

conformable properties,Theytechniques to combine ceils

app=ed to gelatin and co=agen,are also suitable for sol‑gel

Co=agens, gelatins andtransition, meaning that they
can be made into either awith gelatin o｢ co=agen are

we developed a new method for

co=agen peptides haveemerging and are alreadyendotoxin reduction. Since its

distinctive characteristics,

making these new treatment

development, beMatrix丁M has

For example, coilagen has aliquid or gel by adjusting thetemperature and pH. We offer
a unique range of products

been used by researchers andtriple helix structure and is

We recognise that safetycompanies around the wo｢idーan exce=ent biocompatibie

is a top priority, particularly

Fi｢st, researchers use ourmethods more effective.

material. We supply medicalsuch as beMat｢ix丁M, ste｢吊sedat the raw material stage,

materials in animal studies,

device manufacturers,

gelatin solution and coliagen

because it's difficult to remove

and get good results. Next theyuniversities and researchsolution for three‑dimensional

endotoxins or conduct

want to use it in dinical studies,

institutes with a wide range

cuitureノーo name a few.

further purification afterand request from us productsof co=agen products forthe biomate｢iais have beenthat are safe for this purpose.

artificial skin and bone, as

What othe書innovations are iれcombined. We developed

We come up with what they

we= as other regene｢ativethe pipeline?

a unique method to reduceneed for their c=nical study, andmedicine app=cations. Gelatin

innovations arise as aendotoxin levels. Our productafter it's doneノーhey produce

is known for its water‑binding,consequence of combining ourcailed beMatrix了M low

pape｢s○ Other researchers readendotoxin gelatin is of very

those papers and also wanthigh quality and has tessfiim‑forming and adhesive

produds with the user's ideas○

Our goa=s to contribute to global

to directly benefit from ourproperties, and is used in many
applications ranging fromthan ｢o endotoxin units (EU)products.This is the story offood and pharmaceuticals towith various technologies

pe｢g｢am. The US F○○d andhow we developed and released

photosensitised materials･and needs of companies andDrug Administration (FDA)

beMatrix products. Some of the

Co=agen peptides areresearchers. We have recently

guideline regulates endotoxin

researchers who contact us are

increasingly being used indeveioped new types of gelatin

leveis at no more than 20 EUwith companies who develop

dietary supplements and healththat have a ge帖ng temperature

per medjcai device, so this is aremarkabie achievement.

medical devices, bioiogics andfoods, as they can help regulatethat is significantly higher thanregenerative products, a= ofbod=y functions and improvethat of conventional gelatin.

which ut=ize our materials,

skin, bone and joint health,health by combining our materials¥

In 1918, Nitta Gelatin began
producing gelatin and animal⊂aれyou tell us軸○○e
about the deveiopment o書

What a唯軸i慣a Geia置in‑s南ey

What sets N恥a Gelatin apa能glues. ln 2018, as the company

be肌すtri簾l軸亨areas o書busihess?

from otherく○りageh andceiebrates its centena｢y′ webeMatrix丁M was made possible

Our main products aregelatin軸a南ers?

through Nitta Gelatin's

coliagen, gelatin, andRecently there has been a surge

be=eve the potential of co=agen

investment in a state‑oトthe‑arthydroiysed gelatin. Our key

in demand for the biomaterials

and gelatin is infinite.

cleanr○○m fac冊y in 2009 andtechnoiogjes are endotoxin

for medical use and we are we=

produced this specific productand virus reduction. Co=agens

positioned to respond to thisin response to requests fromare a large fam=y of p｢oteinsdemand. We provide co=agen

ADV〔R丁IS且RRE丁AiNintend to keep evolving as weS

S

Oし各i翰N削〇 〇elqlin in⊂.

RESPON

Si8iしi丁Y戸ORCON丁各N丁